NMPA

Advertisement

cGxPJobs Banner

ACR 2025: Phase 3 Telitacicept Results in Sjögren’s Disease

Boston, September 29, 2025 Vor Bio has announced that late-breaking Phase 3 clinical data of telitacicept in primary Sjögren’s...

By cGxPwire Editor
September 29, 2025

Read More

Advertisement

cGxPJobs

Directory